免疫疗法用于治疗非癌基因驱动的可切除非小细胞肺癌：一项真正的变革性疗法，但适用于哪些人群以及何时适用？

01 November 2025


Anand Sachithanandan

在此查看研究
复制引用
已复制！

摘要

参考资料

  1. Pignon, J. P., Tribodet, H., Scagliotti, G. V., Douillard, J. Y., Shepherd, F. A., Stephens, R. J., Dunant, A., Torri, V., Rosell, R., Seymour, L., Spiro, S. G., Rolland, E., Fossati, R., Aubert, D., Ding, K., Waller, D., & Le Chevalier, T. (2008). Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group. Journal of Clinical Oncology, 26(21), 3552–3559. https://doi.org/10.1200/JCO.2007.13.9030
  2. Forde, P. M., Spicer, J., Lu, S., Provencio, M., Mitsudomi, T., Awad, M. M., Felip, E., Broderick, S. R., Brahmer, J. R., Swanson, S. J., Shatsky, R., Rosell, R., Girard, N., Barlesi, F., & PM, F. (2022). Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. The New England Journal of Medicine, 386(21), 1973–1985. https://doi.org/10.1056/NEJMoa2202170
  3. Heymach, J. V., Harpole, D., Mitsudomi, T., Taube, J. M., Galffy, G., Hochmair, M., Weder, W., Papai-Zempleni, Z., Machackova, Z., & D, H. (2023). Perioperative durvalumab for resectable non–small-cell lung cancer. The New England Journal of Medicine, 389(18), 1672–1684. https://doi.org/10.1056/NEJMoa2304875
  4. Cascone, T., Awad, M. M., Spicer, J. D., He, J., Lu, S., Sepesi, B., Tanaka, F., Taube, J. M., Cornelissen, R., Havel, L., Kuzdzal, J., Petruzelka, L., Wu, L., Pujol, J.-L., Ito, H., Coronado Erdmann, C., Sathyanarayana, P., Meadows-Shropshire, S., & Provencio Pulla, M. (2023). LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC. Annals of Oncology, 34(Suppl 2), S1295. https://doi.org/10.1016/j.annonc.2023.10.050
  5. Wakelee, H., Liberman, M., Kato, T., Tsuboi, M., Lee, S.-H., Gao, S., Chen, K.-N., Dooms, C., Majem, M., Eiki, R., Tan, D. S. W., Martin, A., Zhao, J., Piperdi, B., & H, W. (2023). Perioperative pembrolizumab for early-stage non–small-cell lung cancer. The New England Journal of Medicine, 389(6), 491–503. https://doi.org/10.1056/NEJMoa2302983
  6. Lu, S., Zhang, W., Wu, L., Wang, W., Zhang, P., Fang, W., Xing, W., Chen, Q., Yang, L., Mei, J., Tan, L., Sun, X., Xu, S., Hu, X., Yu, G., Yu, D., Yang, N., Chen, Y., Shan, J., … Fang, H. (2024). Perioperative toripalimab plus chemotherapy for patients with resectable non–small cell lung cancer: The Neotorch randomized clinical trial. JAMA, 331(3), 201–211. https://doi.org/10.1001/jama.2023.24735
  7. O’Brien, M., Paz-Ares, L., Marreaud, S., Dafni, U., Oselin, K., Havel, L., Esteban, E., Isla, D., Martinez-Marti, A., Faehling, M., Tufman, A., Thomas, M., Franke, F. A., Roschitztzky-Stuckbrach, A., & M, O. (2022). Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): An interim analysis of a randomised, triple-blind, phase 3 trial. The Lancet Oncology, 23(10), 1274–1286. https://doi.org/10.1016/S1470-2045(22)00518-6
  8. Felip, E., Altorki, N., Zhou, C., Vallières, E., Martínez-Martí, A., Rittmeyer, A., Goloborodko, A., Sezer, A., Reck, M., & E, F. (2023). Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II–IIIA non-small-cell lung cancer (IMpower010): A randomised, multicentre, open-label, phase III trial. Annals of Oncology, 34(10), 907–919. https://doi.org/10.1016/j.annonc.2023.07.001
  9. Provencio, M. (2025, September 8). NADIM ADJUVANT trial suggests benefit of adjuvant chemo-immunotherapy. International Association for the Study of Lung Cancer (IASLC). https://www.iaslc.org/iaslc-news/pressrelease/nadim-adjuvant-trial-suggests-benefit-adjuvant-chemoimmunotherapy
  10. Forde, P. M., Peters, S., Donington, J., Meadows-Shropshire, S., Tran, P., Lucherini, S., Erdmann, C. C., Son, H., & Cascone, T. (2024, September 7–10). Perioperative vs neoadjuvant nivolumab for resectable NSCLC: Patient-level data analysis of CheckMate 77T vs CheckMate 816 [Oral presentation]. IASLC 2024 World Conference on Lung Cancer, San Diego, CA, United States.
  11. Han, Y., Xiao, X., Qin, T., Yao, S., Liu, X., Feng, Y., Li, Z., Li, Y., & Xia, S. (2024). Efficacy and safety of perioperative immunotherapy combinations for resectable non-small cell lung cancer: A systematic review and network meta-analysis. Cancer Immunology, Immunotherapy, 73(12), Article 262. https://doi.org/10.1007/s00262-024-03837-7

引用

Sachithanandan, A. (2025). Immunotherapy for non-oncogene driven resectable non-small cell lung cancer: A true gamechanger but for whom and when? Medical Journal of Malaysia, 80(6), 901-902.

复制引用 已复制！
在此查看研究